- Molecular NameXimelagatran
- SynonymH 376/95; ximelagatran
- Weight473.574
- Drugbank_IDDB04898
- ACS_NO192939-46-1
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)0.71
- pkaN/A
- LogD (pH=7, predicted)0.68
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.49
- LogSw (predicted, AB/LogsW2.0)37.48
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors5
- No.of HBond Acceptors10
- No.of Rotatable Bonds12
- TPSA143.85
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy.
- Absorption_valueN/A
- Absorption (description)Rapidly absorbed by the small intestine with an oral bioavailability of 20%.
- Caco_2N/A
- Bioavailability21.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmXimelagatran is a prodrug, being converted in vivo to the active agent melagatran. This conversion takes place in the liver and many other tissues through dealkylation and dehydroxylation (replacing the ethyl and hydroxyl groups with hydrogen).
- Half life3~5h
- ExcretionRenal (80%)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityHepatotoxicity (liver damage) was reported during trials.
- LD50 (rat)N/A
- LD50 (mouse)N/A